Puma Biotechnology, Inc. (PBYI)

$2.39

+0.07

(+3.02%)▲

Market is closed - opens 7 PM, 11 Sep 2024

Performance

  • $2.26
    $2.40
    $2.39
    downward going graph

    5.44%

    Downside

    Day's Volatility :5.83%

    Upside

    0.42%

    downward going graph
  • $2.13
    $7.73
    $2.39
    downward going graph

    10.88%

    Downside

    52 Weeks Volatility :72.45%

    Upside

    69.08%

    downward going graph

Returns

PeriodPuma Biotechnology, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-35.53%
4.7%
0.0%
6 Months
-59.02%
5.1%
0.0%
1 Year
-33.63%
16.6%
0.0%
3 Years
-68.49%
15.6%
-20.6%

Highlights

Market Capitalization
115.8M
Book Value
$1.0
Earnings Per Share (EPS)
0.19
PE Ratio
12.11
PEG Ratio
0.03
Wall Street Target Price
4.33
Profit Margin
3.98%
Operating Margin TTM
-4.63%
Return On Assets TTM
6.02%
Return On Equity TTM
22.1%
Revenue TTM
219.1M
Revenue Per Share TTM
4.57
Quarterly Revenue Growth YOY
-13.700000000000001%
Gross Profit TTM
172.9M
EBITDA
31.1M
Diluted Eps TTM
0.19
Quarterly Earnings Growth YOY
-0.78
EPS Estimate Current Year
0.26
EPS Estimate Next Year
0.2
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
0.14

Analyst Recommendation

Sell
    12%Buy
    37%Hold
    50%Sell
Based on 8 Wall street analysts offering stock ratings for Puma Biotechnology, Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
3
3
3
Sell
4
4
4

Analyst Forecast

What analysts predicted

Upside of 81.17%

Current $2.39
Target $4.33

Company Financials

FY18Y/Y Change
Revenue
251.0M
↑ 806.14%
Net Income
-113.6M
↓ 61.1%
Net Profit Margin
-45.26%
↑ 1008.89%
FY19Y/Y Change
Revenue
272.3M
↑ 8.49%
Net Income
-82.7M
↓ 27.18%
Net Profit Margin
-30.38%
↑ 14.88%
FY20Y/Y Change
Revenue
225.1M
↓ 17.33%
Net Income
-60.0M
↓ 27.47%
Net Profit Margin
-26.65%
↑ 3.73%
FY21Y/Y Change
Revenue
253.2M
↑ 12.48%
Net Income
-29.1M
↓ 51.5%
Net Profit Margin
-11.49%
↑ 15.16%
FY22Y/Y Change
Revenue
228.0M
↓ 9.95%
Net Income
912.0K
↓ 103.13%
Net Profit Margin
0.4%
↑ 11.89%
FY23Y/Y Change
Revenue
235.6M
↑ 3.35%
Net Income
21.6M
↑ 2267.43%
Net Profit Margin
9.16%
↑ 8.76%
Q1 FY23Q/Q Change
Revenue
52.8M
↓ 19.67%
Net Income
1.4M
↓ 125.02%
Net Profit Margin
2.65%
↑ 11.17%
Q2 FY23Q/Q Change
Revenue
54.6M
↑ 3.4%
Net Income
2.1M
↑ 51.75%
Net Profit Margin
3.9%
↑ 1.25%
Q3 FY23Q/Q Change
Revenue
56.1M
↑ 2.84%
Net Income
5.8M
↑ 172.62%
Net Profit Margin
10.33%
↑ 6.43%
Q4 FY23Q/Q Change
Revenue
72.2M
↑ 28.62%
Net Income
12.3M
↑ 111.66%
Net Profit Margin
17.0%
↑ 6.67%
Q1 FY24Q/Q Change
Revenue
43.8M
↓ 39.36%
Net Income
-4.8M
↓ 139.25%
Net Profit Margin
-11.0%
↓ 28.0%
Q2 FY24Q/Q Change
Revenue
47.1M
↑ 7.58%
Net Income
-4.5M
↓ 5.94%
Net Profit Margin
-9.62%
↑ 1.38%
FY18Y/Y Change
Total Assets
259.1M
↑ 56.55%
Total Liabilities
224.8M
↑ 100.33%
FY19Y/Y Change
Total Assets
234.9M
↓ 9.35%
Total Liabilities
217.4M
↓ 3.28%
FY20Y/Y Change
Total Assets
244.2M
↑ 3.97%
Total Liabilities
250.2M
↑ 15.05%
FY21Y/Y Change
Total Assets
226.6M
↓ 7.22%
Total Liabilities
229.0M
↓ 8.45%
FY22Y/Y Change
Total Assets
222.1M
↓ 2.0%
Total Liabilities
200.5M
↓ 12.48%
FY23Y/Y Change
Total Assets
230.5M
↑ 3.81%
Total Liabilities
177.1M
↓ 11.66%
Q1 FY23Q/Q Change
Total Assets
196.3M
↓ 11.62%
Total Liabilities
170.4M
↓ 14.99%
Q2 FY23Q/Q Change
Total Assets
200.5M
↑ 2.16%
Total Liabilities
170.1M
↓ 0.18%
Q3 FY23Q/Q Change
Total Assets
203.6M
↑ 1.55%
Total Liabilities
164.9M
↓ 3.08%
Q4 FY23Q/Q Change
Total Assets
230.5M
↑ 13.22%
Total Liabilities
177.1M
↑ 7.41%
Q1 FY24Q/Q Change
Total Assets
214.1M
↓ 7.1%
Total Liabilities
163.2M
↓ 7.86%
Q2 FY24Q/Q Change
Total Assets
205.0M
↓ 4.27%
Total Liabilities
156.5M
↓ 4.09%
FY18Y/Y Change
Operating Cash Flow
-24.1M
↓ 86.03%
Investing Cash Flow
-57.6M
↑ 273.3%
Financing Cash Flow
108.4M
↑ 44.34%
FY19Y/Y Change
Operating Cash Flow
22.4M
↓ 192.95%
Investing Cash Flow
5.2M
↓ 108.96%
Financing Cash Flow
-67.1M
↓ 161.9%
FY20Y/Y Change
Operating Cash Flow
800.0K
↓ 96.43%
Investing Cash Flow
23.4M
↑ 353.28%
Financing Cash Flow
100.0K
↓ 100.15%
FY21Y/Y Change
Operating Cash Flow
20.7M
↑ 2487.5%
Investing Cash Flow
-10.9M
↓ 146.49%
Financing Cash Flow
-31.9M
↓ 32000.0%
FY22Y/Y Change
Operating Cash Flow
-15.8M
↓ 176.33%
Investing Cash Flow
7.1M
↓ 165.29%
Financing Cash Flow
12.2M
↓ 138.24%
Q1 FY23Q/Q Change
Operating Cash Flow
2.6M
↓ 65.6%
Investing Cash Flow
-17.5M
↑ 46.97%
Financing Cash Flow
0.0
↓ 100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
3.3M
↑ 24.71%
Investing Cash Flow
-4.7M
↓ 73.16%
Financing Cash Flow
0.0
-

Technicals Summary

Sell

Neutral

Buy

Puma Biotechnology, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
-35.06%
-59.02%
-33.63%
-68.49%
-81.99%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.93%
17.32%
35.75%
73.95%
298.81%
Novo Nordisk A/s
Novo Nordisk A/s
0.96%
-0.08%
31.44%
163.47%
428.79%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-8.66%
65.51%
21.14%
30.19%
192.84%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.75%
12.92%
34.78%
148.18%
173.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
12.11
12.11
0.03
0.26
0.22
0.06
NA
1.0
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Sell
$115.8M
-81.99%
12.11
3.98%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
298.81%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
428.79%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
192.84%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
173.67%
32.84
-4.74%

Insights on Puma Biotechnology, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 43.76M → 47.08M (in $), with an average increase of 7.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.81M → -4.52M (in $), with an average increase of 6.3% per quarter

  • Vs VRTX

    In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 68.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 148.2% return, outperforming this stock by 216.7%

Institutional Holdings

  • Vanguard Group Inc

    7.34%

  • BlackRock Inc

    7.28%

  • Millennium Management LLC

    6.45%

  • Acadian Asset Management LLC

    3.99%

  • Renaissance Technologies Corp

    3.53%

  • Great Point Partners LLC

    3.03%

Company Information

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Organization
Puma Biotechnology, Inc.
Employees
185
CEO
Mr. Alan H. Auerbach
Industry
Health Technology

Discover More

FAQs